Log in for full access to this activity, if you are registered.

Registration Options

Activity Dates: 06/13/2016 - 04/18/2019

Target Audience

This course is designed for pharmacists, nurse practitioners or other healthcare professionals involved in the comprehensive medication management of psychiatric and/or neurological patients.

Session Summary

Antipsychotics are associated with a variety of side effects and include the potential for hematologic issues and blood dyscrasias. Severe neutropenia (formally agranulocytosis) is the most recognized side effect known to occur with clozapine and for which a rigid system of monitoring in the US has been developed. In addition, some patient populations such as patients of African or Middle Eastern descent are known to have differences in normative data ranges which were largely developed in European populations. Thus, Benign Ethnic Neutropenia patients may be perceived to be at risk but may not necessarily have any risk of hematologic complications. Thus, psychiatric pharmacists many times play a role in the identification and treatment of hematologic issues and a better understanding of risks, rationale for guidelines, population differences and treatment options fulfils a much needed gap. This talk will cover blood dyscrasias and hematologic issues with antipsychotic treatment and then focus on issues related to clozapine and the new guidelines that have recently been implemented.

Course Requirements

You will proceed through the following steps to satisfactorily complete this course:

  • Review the full content of the activity and reflect upon its teachings.
  • Complete the post-test at the end of the activity no later than the closing activity date. (login first)
  • Complete the evaluation at the end of the activity. (login first)
  • If necessary, complete the post-test retest no later than the closing activity date. (login first)
  • Receive a passing grade (70%).
  • Provide the necessary details in your profile to ensure correct reporting by CPNP to CPE Monitor. (login first)

This course is provided online at cpnp.org and consists of the speaker audio and slides. A PDF file of the slides is also provided and access is available to participants indefinitely although ACPE credit is available only through the course expiration date.

Participants in this course must complete an examination and achieve a score of 70% or greater. Successful completion of the course also requires the completion of a course evaluation. ACPE statements of credit can be retrieved by participants online at cpnp.org immediately upon successful completion of the course.

Faculty Information and Disclosures

Learning Objectives

  1. Describe the epidemiology, clinical presentation, and consequences of hematological side effects of antipsychotic medications.
  2. Identify and discuss changes to blood monitoring guidelines for clozapine.
  3. Understand the contribution of benign ethnic neutropenia to the risk of hematologic side effects.   
  4. Examine cases of hematologic issues encountered with antipsychotic treatment and discuss treatment options and controversies.

Continuing Education Credit and Disclosures

Activity Dates: 06/13/2016 - 04/18/2019
ACPE Contact Hours: 1.0
ACPE Number: 0284-0000-16-025-H01-P (Knowledge)
Nursing Credit Reminder: Note that ACPE credit is accepted for certification renewal.

ACPEThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This self-study course provides 1.0 contact hours (0.1 CEUs) of knowledge-based continuing education credit from CPNP approved programming. The ACPE universal program number assigned to this course is 0284-0000-16-025-H01-P (1.0 contact hours).